KRAS NP_004976.2:p.G12R

Known as: GTPase KRas G12R, KRAS p.Gly12Arg, KRAS Gly12Arg 
A change in the amino acid residue at position 12 in the GTPase KRas protein where glycine has been replaced by arginine.
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2016
01220092016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
AIMS A 49-year-old man presented with a single thyroid tumour that showed a combination of conventional papillary carcinoma… (More)
Is this relevant?
2017
2017
PTEN inactivation occurs commonly in human cancers and putatively activates the PI3K/AKT/ mTOR pathway. Activation of this… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2016
2016
N-of-1 trials target actionable mutations, yet such approaches do not test genomically-informed therapies in patient tumor models… (More)
Is this relevant?
2014
2014
Lung metastases from primary pancreatic adenocarcinomas often have mucinous features, which makes them difficult to distinguish… (More)
  • table 1
  • table 2
  • figure 2
  • figure 1
  • table 3
Is this relevant?
2014
2014
Aim: Resistance to EGFR tyrosine kinase inhibitors (TKI) is a clinically relevant problem that needs to be addressed by the use… (More)
Is this relevant?
2013
2013
KRAS is one of the most common genes mutated in pancreatic adenocarcinoma. Multiple KRAS mutations may be detected within the… (More)
Is this relevant?
2012
2012
OBJECTIVE To investigate the gene mutation of EGFR and KRAS in Chinese patients with non-small cell lung cancer (NSCLC), and to… (More)
Is this relevant?
2011
2011
Purpose: In thyroid cancer clinical trials, agents targeting VEGF receptors (VEGFR) and RET, among other kinases, have led to… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2011
Review
2011
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Purpose: In… (More)
  • table 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
CONTEXT The V600E mutation accounts for the vast majority of thyroid carcinoma-associated BRAF mutations. OBJECTIVE The aim was… (More)
Is this relevant?